BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Farshbaf M, Valizadeh H, Panahi Y, Fatahi Y, Chen M, Zarebkohan A, Gao H. The impact of protein corona on the biological behavior of targeting nanomedicines. Int J Pharm 2022;614:121458. [PMID: 35017025 DOI: 10.1016/j.ijpharm.2022.121458] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu W, Ye C, Qing X, Liu S, Lv X, Wang W, Dong X, Zhang Y. Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy. Mater Today Bio 2022;16:100358. [PMID: 35880099 DOI: 10.1016/j.mtbio.2022.100358] [Reference Citation Analysis]
2 Mi Z, Yao Q, Qi Y, Zheng J, Liu J, Liu Z, Tan H, Ma X, Zhou W, Rong P. Salmonella-mediated blood‒brain barrier penetration, tumor homing and tumor microenvironment regulation for enhanced chemo/bacterial glioma therapy. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.09.016] [Reference Citation Analysis]
3 Shen M, Wu X, Zhu M, Yi X. Recent advances in biological membrane-based nanomaterials for cancer therapy. Biomater Sci 2022. [PMID: 36017968 DOI: 10.1039/d2bm01044e] [Reference Citation Analysis]
4 Hu H, Xu D. pH-Sensitive nanoparticles co-loaded with dimethylcurcumin and regorafenib for targeted combinational therapy of hepatocellular carcinoma. European Polymer Journal 2022;177:111434. [DOI: 10.1016/j.eurpolymj.2022.111434] [Reference Citation Analysis]
5 Yu Y, Luan Y, Dai W. Time evolution of protein corona formed by polystyrene nanoplastics and urease. Int J Biol Macromol 2022;218:72-81. [PMID: 35870622 DOI: 10.1016/j.ijbiomac.2022.07.104] [Reference Citation Analysis]
6 Cao Y. Nutrient molecule corona: An update for nanomaterial-food component interactions. Toxicology 2022;476:153253. [PMID: 35811011 DOI: 10.1016/j.tox.2022.153253] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Mojarad-Jabali S, Mahdinloo S, Farshbaf M, Sarfraz M, Fatahi Y, Atyabi F, Valizadeh H. Transferrin receptor-mediated liposomal drug delivery: recent trends in targeted therapy of cancer. Expert Opin Drug Deliv 2022;:1-21. [PMID: 35698794 DOI: 10.1080/17425247.2022.2083106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Pandey J, Dubey R, Kate A, Prasad B, Sinha A, Mishra MS. Nanomedicines: A Focus on Nanomaterials as Drug Delivery System with Current Trends and Future Advancement. Drug Res (Stuttg). [DOI: 10.1055/a-1824-4619] [Reference Citation Analysis]
9 Yang R, Wang L, Wu Z, Yin Y, Jiang SW. How Nanotechniques Could Vitalize the O-GlcNAcylation-Targeting Approach for Cancer Therapy. Int J Nanomedicine 2022;17:1829-41. [PMID: 35498390 DOI: 10.2147/IJN.S360488] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wang X, Zhang W. The Janus of Protein Corona on nanoparticles for tumor targeting, immunotherapy and diagnosis. J Control Release 2022:S0168-3659(22)00189-4. [PMID: 35367478 DOI: 10.1016/j.jconrel.2022.03.056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Farshbaf M, Mojarad-Jabali S, Hemmati S, Khosroushahi AY, Motasadizadeh H, Zarebkohan A, Valizadeh H. Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers. J Control Release 2022:S0168-3659(22)00145-6. [PMID: 35301054 DOI: 10.1016/j.jconrel.2022.03.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]